Efficacy of Intramyocardial Injection of Angiogenic Cell Precursors for Ischemic Cardiomyopathy

Arom, Kitipan V.; Ruengsakulrach, Permyos; Jotisakulratana, Vibul

doi:10.1177/155698450800300109

Cited by 1 publication

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Those patients who had undergone intramyocardial ACPs injection tended to have improvement in NYHA functional class and LVEF than in the controls. 24,25 The future researches areas are many: (1) the explorations of new types of cells, e.g. resident cardiac progenitor cell, umbilical cord blood stem cells, induced pluripotent stem cells or combined stem cells, (2) creation of a receptive cell environment, (3) timing of stem cell therapy, (4) non-invasive in vivo cell tracking, (5) pharmacologic manipulation or combined gene therapy, (6) repeated cell injections and (7) heart tissue engineering.…”

Section: Discussionmentioning

confidence: 99%

Midterm Results of Surgical Intramyocardial Implantation of Autologous Angiogenic Cell Precursors for Cardiomyopathy

Ruengsakulrach¹,

Pitiguagool²,

Pamornsing³

et al. 2017

bkkmedj

Self Cite

View full text Add to dashboard Cite

C ardiomyopathies are primary (i.e., genetic, mixed, or acquired) or secondary (e.g., infiltrative, toxic, inflammatory) and lead to progressive heart failure with significant morbidity and mortality. 1 Dilated cardiomyopathy (DCM) is classified as a mixed (genetic and nongenetic) primary cardiomyopathy. DCM manifests clinically at a wide range of ages and is characterized by ventricular chamber enlargement and systolic dysfunction which leads to progressive heart failure and a decline in left ventricular function, ventricular and supraventricular arrhythmias, conduction system abnormalities, thromboembolism, and sudden or heart failure-related death. Indeed, DCM is a common and largely irreversible form of heart muscle disease. It is the most frequent cause of heart transplantation. Coronary artery disease is one of the most frequent causes of heart failure (HF). There is no uniform definition for ischemic cardiomyopathy (ICM). Despite improvements with medical treatment, the prognosis of patients with end-stage HF remains poor. The median survival was 4 years after the onset of HF. One-year survival was 72% and 5-year survival was 45% after the onset of HF. 2 Revascularization of nonviable myocardium has not proven to be beneficial in terms of either mortality or improvement of left ventricular function. Heart transplantation is currently the best treatment option for end-stage cardiomyopathy however it is limited by a shortage of donors. In this study, we only included patients with DCM and ICM.

show abstract

Section: Discussionmentioning

confidence: 99%